Using MEK, BRAF and SHP2 inhibitors, he demonstrated the potential therapeutic advantage of combined BRAF and SHP2 inhibition in MEKi-resistant BRAF mutant glioma preclinical models. This evidence concerns the gene PTPN11 and central nervous system cancer.